Vasim Farooq

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5891834/publications.pdf

Version: 2024-02-01

133	6,568	50276	69250
papers	citations	46 h-index	77 g-index

134	134	134	5353
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet, The, 2013, 381, 639-650.	13.7	679
2	Quantification of Incomplete Revascularization and its Association With Five-Year Mortality in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) Trial Validation of the Residual SYNTAX Score. Circulation, 2013, 128, 141-151.	1.6	326
3	Improved Safety and Reduction in Stent Thrombosis Associated With Biodegradable Polymer-Based Biolimus-Eluting Stents Versus Durable Polymer-Based Sirolimus-Eluting Stents in Patients With Coronary Artery Disease. JACC: Cardiovascular Interventions, 2013, 6, 777-789.	2.9	296
4	The Negative Impact of Incomplete Angiographic Revascularization on Clinical Outcomes and Its Association With Total Occlusions. Journal of the American College of Cardiology, 2013, 61, 282-294.	2.8	257
5	Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study. European Heart Journal, 2017, 38, 3124-3134.	2.2	244
6	Restenosis. Circulation: Cardiovascular Interventions, 2011, 4, 195-205.	3.9	165
7	Comparison of intravascular ultrasound versus angiography-guided drug-eluting stent implantation: a meta-analysis of one randomised trial and ten observational studies involving 19,619 patients. EuroIntervention, 2012, 8, 855-865.	3.2	163
8	Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy?. European Heart Journal, 2012, 33, 1325-1333.	2.2	138
9	Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the Logistic Clinical SYNTAX score. European Heart Journal, 2012, 33, 3098-3104.	2.2	138
10	Incidence and multivariable correlates of long-term mortality in patients treated with surgical or percutaneous revascularization in the Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) trial. European Heart Journal, 2012, 33, 3105-3113.	2.2	119
11	Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: Can the scaffold cap the plaque?. Atherosclerosis, 2012, 221, 106-112.	0.8	115
12	ABSORB II randomized controlled trial. American Heart Journal, 2012, 164, 654-663.	2.7	113
13	Effect of the Endothelial Shear Stress Patterns on Neointimal Proliferation Following Drug-Eluting Bioresorbable Vascular Scaffold Implantation. JACC: Cardiovascular Interventions, 2014, 7, 315-324.	2.9	108
14	Incidence and Short-Term Clinical Outcomes of Small Side Branch Occlusion After Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold. JACC: Cardiovascular Interventions, 2013, 6, 247-257.	2.9	98
15	Long-term forecasting and comparison of mortality in the Evaluation of the Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial: prospective validation of the SYNTAX Score II. European Heart Journal, 2015, 36, 1231-1241.	2.2	98
16	Outcomes After Percutaneous Coronary Intervention or Bypass Surgery in Patients With Unprotected Left Main Disease. Journal of the American College of Cardiology, 2016, 68, 999-1009.	2.8	95
17	Emerging technologies: polymer-free phospholipid encapsulated sirolimus nanocarriers for the controlled release of drug from a stent-plus-balloon or a stand-alone balloon catheter. EuroIntervention, 2013, 9, 148-156.	3.2	93
18	Fractional Flow Reserve Derived From Computed Tomographic Angiography in Patients With Multivessel CAD. Journal of the American College of Cardiology, 2018, 71, 2756-2769.	2.8	92

#	Article	IF	Citations
19	A Global Risk Approach to Identify Patients With Left Main or 3-Vessel Disease Who Could Safely and Efficaciously Be Treated With Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2012, 5, 606-617.	2.9	91
20	Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. American Journal of Kidney Diseases, 2004, 43, 531-537.	1.9	89
21	Intracoronary Optical Coherence Tomography and Histology of Overlapping Everolimus-Eluting Bioresorbable Vascular Scaffolds in a Porcine Coronary Artery Model. JACC: Cardiovascular Interventions, 2013, 6, 523-532.	2.9	84
22	Serial Analysis of the Malapposed and Uncovered Struts of the New Generation of Everolimus-Eluting Bioresorbable Scaffold With Optical Coherence Tomography. JACC: Cardiovascular Interventions, 2011, 4, 992-1001.	2.9	75
23	The SYNTAX score and its clinical implications. Heart, 2014, 100, 169-177.	2.9	75
24	Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial. Heart, 2013, 99, 98-105.	2.9	72
25	Clinical Implication of Quantitative Flow Ratio After Percutaneous Coronary Intervention for 3-Vessel Disease. JACC: Cardiovascular Interventions, 2019, 12, 2064-2075.	2.9	71
26	The CABG SYNTAX Score - an angiographic tool to grade the complexity of coronary disease following coronary artery bypass graft surgery: from the SYNTAX Left Main Angiographic (SYNTAX-LE MANS) substudy. EuroIntervention, 2013, 8, 1277-1285.	3.2	71
27	Clinical and Angiographic Characteristics of Patients Likely to Have Vulnerable Plaques. JACC: Cardiovascular Imaging, 2013, 6, 1263-1272.	5.3	67
28	Coronary evaginations are associated with positive vessel remodelling and are nearly absent following implantation of newer-generation drug-eluting stents: an optical coherence tomography and intravascular ultrasound study. European Heart Journal, 2014, 35, 795-807.	2.2	67
29	Contemporary and evolving risk scoring algorithms for percutaneous coronary intervention. Heart, 2011, 97, 1902-1913.	2.9	65
30	Widening clinical applications of the SYNTAX Score. Heart, 2014, 100, 276-287.	2.9	64
31	Predictive Performance of SYNTAX Score II in Patients With Left Main and Multivessel Coronary Artery Disease. Circulation Journal, 2014, 78, 1942-1949.	1.6	64
32	Short-Term and Long-Term Clinical Impact of Stent Thrombosis and Graft Occlusion in the SYNTAX Trial at 5 Years. Journal of the American College of Cardiology, 2013, 62, 2360-2369.	2.8	62
33	CT-SYNTAX Score. JACC: Cardiovascular Imaging, 2013, 6, 413-415.	5.3	62
34	Head-to-Head Comparison of the Neointimal Response Between Metallic and Bioresorbable Everolimus-Eluting Scaffolds Using Optical Coherence Tomography. JACC: Cardiovascular Interventions, 2011, 4, 1271-1280.	2.9	61
35	Vascular Compliance Changes of the Coronary Vessel Wall After Bioresorbable Vascular Scaffold Implantation in the Treated and Adjacent Segments. Circulation Journal, 2012, 76, 1616-1623.	1.6	57
36	Bioresorbable scaffolds: a new paradigm in percutaneous coronary intervention. BMC Cardiovascular Disorders, 2016, 16, 38.	1.7	57

#	Article	IF	Citations
37	Bioresorbable scaffolds: Current knowledge, potentialities and limitations experienced during their first clinical applications. International Journal of Cardiology, 2013, 167, 11-21.	1.7	56
38	Prediction of 1-Year Mortality in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2013, 6, 737-745.	2.9	54
39	Three-dimensional optical frequency domain imaging in conventional percutaneous coronary intervention: the potential for clinical application. European Heart Journal, 2013, 34, 875-885.	2.2	54
40	Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: final results of the SYNTAX II study. European Heart Journal, 2022, 43, 1307-1316.	2.2	54
41	New Insights Into the Coronary Artery Bifurcation. JACC: Cardiovascular Interventions, 2011, 4, 921-931.	2.9	53
42	Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study. EuroIntervention, 2012, 8, 214-224.	3.2	51
43	Angiographic Geometric Changes of the Lumen Arterial Wall After Bioresorbable Vascular Scaffolds and Metallic Platform Stents at 1-Year Follow-Up. JACC: Cardiovascular Interventions, 2011, 4, 789-799.	2.9	48
44	Prognostic Value of Site SYNTAX Score and Rationale for Combining Anatomic and Clinical Factors in Decision Making. Journal of the American College of Cardiology, 2014, 64, 423-432.	2.8	48
45	Impact of 3-Dimensional Bifurcation Angle on 5-Year Outcome of Patients After Percutaneous Coronary Intervention for Left Main Coronary Artery Disease. JACC: Cardiovascular Interventions, 2013, 6, 1250-1260.	2.9	47
46	Comparison of in vivo eccentricity and symmetry indices between metallic stents and bioresorbable vascular scaffolds: Insights from the ABSORB and SPIRIT trials. Catheterization and Cardiovascular Interventions, 2012, 79, 219-228.	1.7	46
47	Angiography-Derived Fractional Flow Reserve in the SYNTAX II Trial. JACC: Cardiovascular Interventions, 2019, 12, 259-270.	2.9	46
48	The use of a guide catheter extension system as an aid during transradial percutaneous coronary intervention of coronary artery bypass grafts. Catheterization and Cardiovascular Interventions, 2011, 78, 847-863.	1.7	45
49	6-Month Clinical Outcomes Following Implantation of the Bioresorbable Everolimus-Eluting Vascular Scaffold in Vessels Smaller or Larger Than 2.5 mm. Journal of the American College of Cardiology, 2011, 58, 258-264.	2.8	44
50	Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data. EuroIntervention, 2015, 11, 746-756.	3.2	42
51	Assessment of coronary atherosclerosis by IVUS and IVUS-based imaging modalities: progression and regression studies, tissue composition and beyond. International Journal of Cardiovascular Imaging, 2011, 27, 225-237.	1.5	38
52	Proximal and distal maximal luminal diameters as a guide to appropriate deployment of the ABSORB everolimusâ€eluting bioresorbable vascular scaffold. Catheterization and Cardiovascular Interventions, 2012, 79, 880-888.	1.7	38
53	Optical coherence tomography (OCT) of overlapping bioresorbable scaffolds: from benchwork to clinical application. EuroIntervention, 2011, 7, 386-399.	3.2	37
54	Clinical outcomes after zotarolimus and everolimus drug eluting stent implantation in coronary artery bifurcation lesions: insights from the RESOLUTE All Comers Trial. Heart, 2013, 99, 1267-1274.	2.9	36

#	Article	IF	Citations
55	Vascular Response of the Segments Adjacent to the Proximal and Distal Edges of the ABSORB Everolimus-Eluting Bioresorbable Vascular Scaffold: 6-Month and 1-Year Follow-Up Assessment. JACC: Cardiovascular Interventions, 2012, 5, 656-665.	2.9	35
56	Progress in Treatment by Percutaneous Coronary Intervention: The Stent of the Future. Revista Espanola De Cardiologia (English Ed), 2013, 66, 483-496.	0.6	34
57	Estimates of absolute treatment benefit for individual patients required careful modeling of statistical interactions. Journal of Clinical Epidemiology, 2015, 68, 1366-1374.	5.0	34
58	Bioresorbable Scaffolds: Current Evidence and Ongoing Clinical Trials. Current Cardiology Reports, 2012, 14, 626-634.	2.9	33
59	Defining Percutaneous Coronary Intervention Complexity and Risk. JACC: Cardiovascular Interventions, 2022, 15, 39-49.	2.9	33
60	Edge Vascular Response After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2013, 6, 211-221.	2.9	31
61	Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE Program. Heart, 2013, 99, 626-633.	2.9	31
62	Geographical Difference of the Interaction of Sex With Treatment Strategy in Patients With Multivessel Disease and Left Main Disease. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	31
63	Comparison of acute gain and late lumen loss after PCI with bioresorbable vascular scaffolds versus everolimus-eluting stents: an exploratory observational study prior to a randomised trial. EuroIntervention, 2014, 10, 672-680.	3.2	30
64	Transcatheter aortic valve implantation: new developments and upcoming clinical trials. EuroIntervention, 2012, 8, 617-627.	3.2	30
65	Agreement and reproducibility of grayâ€scale intravascular ultrasound and optical coherence tomography for the analysis of the bioresorbable vascular scaffold. Catheterization and Cardiovascular Interventions, 2012, 79, 890-902.	1.7	29
66	Validation of the SYNTAX Revascularization Index to Quantify Reasonable Level of Incomplete Revascularization After Percutaneous Coronary Intervention. American Journal of Cardiology, 2015, 116, 174-186.	1.6	29
67	Different cardiac biomarkers to detect peri-procedural myocardial infarction in contemporary coronary stent trials: impact on outcome reporting. Heart, 2012, 98, 1424-1430.	2.9	27
68	The severity of muscle ischemia during intermittent claudication. Journal of Vascular Surgery, 2002, 36, 89-93.	1.1	26
69	Validity of SYNTAX score II for risk stratification of percutaneous coronary interventions: A patient-level pooled analysis of 5433 patients enrolled in contemporary coronary stent trials. International Journal of Cardiology, 2015, 187, 111-115.	1.7	26
70	Impact of postâ€procedural minimal stent area on 2â€year clinical outcomes in the SYNTAX II trial. Catheterization and Cardiovascular Interventions, 2019, 93, E225-E234.	1.7	26
71	Relationship Between Palpography and Virtual Histology in Patients With Acute Coronary Syndromes. JACC: Cardiovascular Imaging, 2012, 5, S19-S27.	5.3	23
72	Rationale and design of the SYNTAX II trial evaluating the short to long-term outcomes of state-of-the-art percutaneous coronary revascularisation in patients with de novo three-vessel disease. EuroIntervention, 2016, 12, e224-e234.	3.2	23

#	Article	IF	Citations
73	The SYNTAX Score and SYNTAX-Based Clinical Risk Scores. Seminars in Thoracic and Cardiovascular Surgery, 2011, 23, 99-105.	0.6	22
74	Future perspectives in transcatheter aortic valve implantation. International Journal of Cardiology, 2013, 168, 11-18.	1.7	20
75	Circumferential distribution of the neointima at six-month and two-year follow-up after a bioresorbable vascular scaffold implantation: a substudy of the ABSORB Cohort B Clinical Trial. EuroIntervention, 2015, 10, 1299-1306.	3.2	20
76	Serial In Vivo Intravascular Ultrasound-Based Echogenicity Changes of Everolimus-Eluting Bioresorbable Vascular Scaffold During the First 12 Months After Implantation. JACC: Cardiovascular Interventions, 2011, 4, 1281-1289.	2.9	19
77	3-Dimensional reconstruction of a bifurcation lesion with double wire after implantation of a second generation everolimus-eluting bioresorbable vascular scaffold. International Journal of Cardiology, 2011, 153, e43-e45.	1.7	19
78	Risk stratification in 3â€vessel coronary artery disease: Applying the <scp>SYNTAX</scp> Score <scp>II</scp> in the Heart Team Discussion of the <scp>SYNTAX</scp><scp>II</scp> trial. Catheterization and Cardiovascular Interventions, 2015, 86, E229-38.	1.7	19
79	Are Higher Operator Volumes for Unprotected Left Main Stem Percutaneous Coronary Intervention Associated With Improved Patient Outcomes?. Circulation: Cardiovascular Interventions, 2020, 13, e008782.	3.9	19
80	Bioresorbable scaffolds in the treatment of coronary artery disease. Medical Devices: Evidence and Research, 2013, 6, 37.	0.8	17
81	The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials. EuroIntervention, 2013, 9, 709-720.	3.2	17
82	In vivo assessment of the three-dimensional haemodynamic micro-environment following drug-eluting bioresorbable vascular scaffold implantation in a human coronary artery: fusion of frequency domain optical coherence tomography and angiography. EuroIntervention, 2013, 9, 890-890.	3.2	17
83	Three-Dimensional Reconstruction of the Post-Dilated ABSORB Everolimus-Eluting Bioresorbable Vascular Scaffold in a True Bifurcation Lesion for Flow Restoration. JACC: Cardiovascular Interventions, 2011, 4, 1149-1150.	2.9	16
84	Evaluation with in vivo optical coherence tomography and histology of the vascular effects of the everolimus-eluting bioresorbable vascular scaffold at two years following implantation in a healthy porcine coronary artery model: implications of pilot results for future pre-clinical studies. International Journal of Cardiovascular Imaging, 2012, 28, 499-511.	1.5	16
85	Relationship Between Femoral Vascular Closure Devices and Short-Term Mortality From 271 845 Percutaneous Coronary Intervention Procedures Performed in the United Kingdom Between 2006 and 2011. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	16
86	Incidence, correlates, and significance of abnormal cardiac enzyme rises in patients treated with surgical or percutaneous based revascularisation. International Journal of Cardiology, 2013, 168, 5287-5292.	1.7	15
87	Cost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspective. Heart, 2015, 101, 1980-1988.	2.9	15
88	ApPropriateness of myocaRdial RevascularizatiOn assessed by the SYNTAX score II in a coUntry without cardiac Surgery faciliTies; PROUST study. International Journal of Cardiology, 2017, 227, 478-484.	1.7	15
89	The coronary artery bypass graft SYNTAX Score: final five-year outcomes from the SYNTAX-LE MANS left main angiographic substudy. EuroIntervention, 2013, 9, 1009-1010.	3.2	15
90	Utilizing Risk Scores in Determining the Optimal Revascularization Strategy for Complex Coronary Artery Disease. Current Cardiology Reports, 2011, 13, 415-423.	2.9	14

#	Article	IF	Citations
91	Analysis of 1Âyear virtual histology changes in coronary plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold. International Journal of Cardiovascular Imaging, 2012, 28, 1307-1314.	1.5	13
92	SYNTAX score II â€“ Authors' reply. Lancet, The, 2013, 381, 1899-1900.	13.7	13
93	Tools and Techniques - Clinical: SYNTAX score II calculator. EuroIntervention, 2016, 12, 120-123.	3.2	12
94	3-Dimensional optical frequency domain imaging for the evaluation of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction. International Journal of Cardiology, 2011, 151, 103-105.	1.7	11
95	â€œCherry-Pickingâ€•Patients for Randomized, Controlled Trialsâ€”Reliving the Pastâ€¦. Journal of the American College of Cardiology, 2013, 61, 2492.	2.8	11
96	Short- and Long-Term Implications of a Bioresorbable Vascular Scaffold Implantation on the Local Endothelial Shear Stress Patterns. JACC: Cardiovascular Interventions, 2014, 7, 100-101.	2.9	11
97	Rotational Atherectomy Complicated by Coronary Perforation Is Associated With Poor Outcomes: Analysis of 10,980 Cases From the British Cardiovascular Intervention Society Database. Cardiovascular Revascularization Medicine, 2021, 28, 9-13.	0.8	11
98	Excimer laser coronary atherectomy during complex PCI: An analysis of 1,471 laser cases from the British Cardiovascular Intervention Society database. Catheterization and Cardiovascular Interventions, 2021, 97, E653-E660.	1.7	10
99	Unravelling the complexities of the coronary bifurcation: is this raising a few eyebrows?. EuroIntervention, 2012, 7, 1133-1141.	3.2	10
100	Plaque Compositional Syntax Score. JACC: Cardiovascular Imaging, 2012, 5, S119-S121.	5.3	9
101	Forward and back aspiration during ST-elevation myocardial infarction: a feasibility study. EuroIntervention, 2016, 11, e1639-e1648.	3.2	9
102	Clinical outcome of patients with stable ischaemic heart disease as compared to those with acute coronary syndromes after percutaneous coronary intervention. EuroIntervention, 2015, 11, 171-179.	3.2	9
103	Feasibility of hybrid off pump artery bypass grafting and transaortic transcatheter aortic valve implantation: A case series. Catheterization and Cardiovascular Interventions, 2017, 89, 1273-1279.	1.7	8
104	Clinical and angiographic outcomes following first-in-man implantation of a novel thin-strut low-profile fixed-wire stent: the Svelte Coronary Stent Integrated Delivery System first-in-man trial. EuroIntervention, 2013, 9, 125-134.	3.2	8
105	Assessment of plaque evolution in coronary bifurcations located beyond everolimus eluting scaffolds: serial intravascular ultrasound virtual histology study. Cardiovascular Ultrasound, 2013, 11, 25.	1.6	7
106	Bypass Grafting Versus Percutaneous Interventionâ€”Which Is Better in Multivessel Coronary Disease: Lessons From SYNTAX and Beyond. Progress in Cardiovascular Diseases, 2015, 58, 316-334.	3.1	7
107	Revisiting: â€œComparison of intravascular ultrasound versus angiography-guided drug-eluting stent implantation: a meta-analysis of one randomised trial and ten observational studies involving 19,619 patientsâ€• EuroIntervention, 2013, 9, 891-892.	3.2	7
108	Serial 2- and 3-Dimensional Visualization of Side Branch Jailing After Metallic Stent Implantation. JACC: Cardiovascular Interventions, 2012, 5, 1089-1090.	2.9	6

#	Article	IF	Citations
109	3D Reconstructions of Optical Frequency Domain Imaging to Improve Understanding of Conventional PCI. JACC: Cardiovascular Imaging, 2011, 4, 1044-1046.	5.3	5
110	In vivo three dimensional optical coherence tomography. A novel imaging modality to visualize the edge vascular response. International Journal of Cardiology, 2013, 164, e35-e37.	1.7	5
111	Recurrent Balloon Rupture During Transcatheter Aortic Valve Replacement (TAVR) â€“ Implication for Access Site Choice. Heart Lung and Circulation, 2015, 24, e193-e194.	0.4	5
112	Usefulness of the updated logistic clinical SYNTAX score after percutaneous coronary intervention in patients with prior coronary artery bypass graft surgery: Insights from the GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions, 2020, 96, E516-E526.	1.7	5
113	A guide to interpreting and assessing the performance of prediction models. EuroIntervention, 2011, 6, 909-912.	3.2	5
114	Lipid core burden index and Framingham score: Can a Systemic Risk Score predict lipid core burden in non-culprit coronary artery?. International Journal of Cardiology, 2012, 156, 211-213.	1.7	4
115	Complex Coronary Artery Disease. JACC: Cardiovascular Interventions, 2013, 6, 1023-1025.	2.9	4
116	Combined use of rotational and excimer lASER coronary atherectomy (RASER) during complex coronary angioplastyâ€”An analysis of cases (2006â€“2016) from the British Cardiovascular Intervention Society database. Catheterization and Cardiovascular Interventions, 2021, 97, E911-E918.	1.7	4
117	Use of the Sideguard (Cappella) stent in bifurcation lesions: a real-world experience. EuroIntervention, 2012, 7, 1170-1180.	3.2	4
118	Angiographic and histological results following implantation of a novel stent-on-a-wire in the animal model. EuroIntervention, 2012, 8, 390-399.	3.2	4
119	Balancing idealism with realism to safeguard the welfare of patients: The importance of Heart Team led decision-making in patients with complex coronary artery disease. Indian Heart Journal, 2016, 68, 1-5.	0.5	3
120	Cherry-Picking Historical Data to Legitimize Contemporary Practice. Journal of the American College of Cardiology, 2017, 69, 404-408.	2.8	3
121	The triad of residual ischaemia, plaque burden, and plaque vulnerability: a known known?â€¦a known unknown?...or an unknown unknown?. EuroIntervention, 2015, 11, 611-619.	3.2	3
122	Observations from the CREDO-Kyoto three-vessel disease registry: can one adjust for the unadjustable?. EuroIntervention, 2013, 9, 419-421.	3.2	3
123	Tools & Techniques: Risk stratification and diagnostic tools in left main stem intervention. EuroIntervention, 2011, 7, 747-753.	3.2	3
124	The impact of coronary perforation in percutaneous interventions involving the left main stem coronary artery in the United Kingdom 2007â€“2014: Insights from the British Cardiovascular Intervention Society database. Catheterization and Cardiovascular Interventions, 2021, 97, E179-E185.	1.7	2
125	Serial optical coherence tomography of drug-eluting stent in-stent restenosis treated with the Absorb bioresorbable scaffold: an effective treatment?. EuroIntervention, 2015, 10, e1-e1.	3.2	2
126	Response to Letter Regarding Article, â€œQuantification of Incomplete Revascularization and Its Association With Five-Year Mortality in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) Trial: Validation of the Residual SYNTAX Scoreâ€. Circulation, 2014, 129, e355-6.	1.6	1

#	Article	IF	Citations
127	Neoatherosclerosis, plaque rupture and very late stent thrombosis of a first generation drug eluting stent treated with aspiration thrombectomy and newer generation drug eluting stent implantation. International Journal of Cardiology, 2015, 201, 648-649.	1.7	1
128	Response by Farooq et al to Letter Regarding Article, â€œRelationship Between Femoral Vascular Closure Devices and Short-Term Mortality From 271â€‰845 Percutaneous Coronary Intervention Procedures Performed in the United Kingdom Between 2006 and 2011: A Propensity Scoreâ€“Corrected Analysis From the British Cardiovascular Intervention Societyâ€• Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	1
129	Left main coronary intervention: Are we moving too quickly without the appropriate evidence base?. Catheterization and Cardiovascular Interventions, 2012, 80, 213-214.	1.7	0
130	Chronic Total Occlusions. JACC: Cardiovascular Interventions, 2017, 10, 889-891.	2.9	0
131	Vascular complications associated with intraaortic balloon pump supported percutaneous coronary intervention (PCI) and clinical outcomes from the British Cardiovascular Intervention Society National PCI Database. Catheterization and Cardiovascular Interventions, 2021, 98, E53-E61.	1.7	0
132	Lessons from acute and late scaffold failures in the ABSORB EXTEND trial: have we really learned them all?. EuroIntervention, 2014, 10, 419-423.	3.2	0
133	The Impact of Intracoronary Imaging on PCI Outcomes in Cases Utilising Rotational Atherectomy: An Analysis of 8,417 Rotational Atherectomy Cases from the British Cardiovascular Intervention Society Database. Journal of Interventional Cardiology, 2022, 2022, 1-9.	1.2	0